Linna Wang

ORCID：0000-0001-7160-9241

发表论文 51 篇 · 总被引 2474 次 · h-index 18

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study (2023 · The Lancet · 被引 729)
• Calcium-dependent activation of CPK12 facilitates its cytoplasm-to-nucleus translocation to potentiate plant hypoxia sensing by phosphorylating ERF-VII transcription factors (2023 · Molecular Plant · 被引 95)
• Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial (2022 · BMC Medicine · 被引 86)
• SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study (2022 · Clinical Cancer Research · 被引 61)
• Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial (2021 · International Journal of Cancer · 被引 50)
• Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study (2021 · Drug Design Development and Therapy · 被引 31)